Soumya Poddar

A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)

E. Lee, U. Gerdemann, C. Jacobson, 2022, Blood.

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

S. Neelapu, O. Oluwole, A. Kilcoyne, 2022, Blood.

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

S. de Vos, C. Jacobson, S. Neelapu, 2023, Blood.